Fungal infections such as athlete's foot, ringworm infection, serious systemic infections, and others are spreading rapidly across the globe and a number of treatments are available to treat these diseases. Rising incidence of immunological disease and availability of a wide range of products have driven the growth of the global antifungal treatment market. Furthermore, rising awareness about side effects of traditional drugs and availability of new drugs favor the growth of the market.
The anti-fungal treatment market is expected to cross USD 25,764.67 million by 2027 at a CAGR of 6.35%.
Some of the key players in this market are Novartis AG (Switzerland), Pfizer Inc. (U.S), Sanofi (France), Merck & Co., Inc. (U.S), Astellas (Japan), Bayer AG (Germany)
The global antifungal treatment market has been segmented on the basis of drugs class, which includes azoles, pyrimidines, echinocandins, polyenes, allylamines, and others drugs.
On the basis of therapeutic indication, the market is segmented into systemic, candidiasis, coccidioidomycosis, and cryptococcosis.
On the basis of pathogen, the market is segmented into Candida, Aspergillus, Cryptococcus, Coccidioides immitis, Zygomycetes, Trichophyton, and others.
On the basis of end users, the market is segmented into hospitals & clinics, dermatology clinics and other users.
Europe is the second largest antifungal treatment market and holds a noticeable share in the global antifungal treatment market. The European market is expected to grow significantly during the forecast period owing to availability of advanced treatment facilities, skilled medical professionals, and adoption of new therapies.
Increasing prevalence of HIV in Asia Pacific region is the key factor for the market growth. Rising awareness about the antifungal treatment and availability of new treatment methods drive the market in Asia Pacific region. In Asia Pacific, the market shows growth opportunities in China and India. China is expected to be the fastest growing market with the CAGR of 5.24% during the forecasted period.
The Middle East & Africa is expected to show the least growth in this market due to some major factors such as lack of awareness about the anti-fungal treatment, limited access and availability of treatment facilities, low income etc.
The report on the Global Anti-fungal Treatment Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions
|Market Size||2027: USD 25,764.67 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Novartis AG (Switzerland), Pfizer Inc. (U.S), Sanofi (France), Merck & Co., Inc. (U.S), Astellas (Japan), Bayer AG (Germany)|
|Key Market Opportunities||
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
The main drug class of Antifungal Treatment Market are Azoles, Pyrimidines, Echinocandins, Polyenes, Allylamines
The global antifungal treatment market can exhibit 6.35% CAGR from 2017 to 2023.
The APAC region can display a CAGR of 4.88% from 2017 to 2023.
The Americas held a valuation of USD 5,539.4 million in 2016 in the global antifungal treatment market.
Bayer AG, Astellas, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi are major players of the global antifungal treatment market.
The global antifungal treatment market is expected to touch a value of USD 25,764.67 million by 2023.